低血糖和发生的大动脉狭窄:一个队列研究
Viktor Lind1,2, Pia Lundman3,2, Leif Friberg3
1Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden viktor.lind@ki.se.
Heart (British Cardiac Society)
|February 6, 2025
概括
血糖水平升高,即使低于糖尿病值,也会增加发生大动脉狭窄的风险. 这一发现强调了控制失糖症对心血管健康的重要性.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 大动脉狭窄是一种严重的退行性心脏病,目前没有预防性治疗方法.
- 糖尿病是已知的危险因素,但低于糖尿病值的葡萄糖水平对大动脉狭窄发展的影响尚不清楚.
研究的目的:
- 调查失糖症 (包括禁食葡萄糖受损) 与大动脉狭窄发生率之间的关联.
主要方法:
- 分析了来自瑞典阿波脂蛋白死亡风险队列 (1985-1996) 的324,449名参与者,记录了禁食葡萄糖和脂质水平.
- 到2020年12月,对发生的大动脉狭窄的随访,将空腹葡萄糖分为低,正常,失效的空腹葡萄糖,高葡萄糖和糖尿病.
- 考克斯的比例危险模型用于调整的危险比率 (HR) 计算,考虑了各种风险因素.
主要成果:
- 在25.9年的时间里,有8523例大动脉狭窄病例被记录在案.
- 与正常葡萄糖水平相比,失调的禁食葡萄糖 (HR 1.36),高葡萄糖 (HR 1.79) 和糖尿病 (HR 2.21) 与大动脉狭窄风险显著增加有关.
- 随着葡萄糖水平的上升,风险不断增加,甚至低于受损的禁食葡萄糖值.
结论:
- 低血糖症,包括低于糖尿病范围的葡萄糖水平,与大动脉狭窄症的风险增加有关.
- 这些发现表明,即使在糖尿病前的范围内,控制葡萄糖水平也可能对预防大动脉狭窄至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
499
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
499
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
146
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
146


